However, in patients with T2D, CKD, and NAFLD, GLP-1 receptor agonists and SGLT2 inhibitors are highly recommended, not only for their glucose-lowering properties but also for their cardioprotective, hepatoprotective, and nephroprotective benefits [111]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.